Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9), mainly secreted in the liver, is a key regulator of cholesterol homeostasis inducing LDL receptors’ degradation. Beyond lipid metabolism, PCSK9 is involved in the development of atherosclerosis, promoting plaque formation in mice and human, impairing the integrity of endothelial monolayer and promoting the events that induce atherosclerosis disease progression. In addition, the PCSK9 ancillary role in the atherothrombosis process is widely debated. Indeed, recent evidence showed a regulatory effect of PCSK9 on redox system and platelet activation. In particular, the role of PCSK9 in the activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox2) system, of MAP-kinase cascades and of CD36 and LOX-1 downstream pathways, suggests that PCSK9 may be a significant cofactor in atherothrombosis development. This evidence suggests that the serum levels of PCSK9 could represent a new biomarker for the occurrence of cardiovascular events. Finally, other evidence showed that PCSK9 inhibitors, a novel pharmacological tool introduced in clinical practice in recent years, counteracted these phenomena. In this review, we summarize the evidence concerning the role of PCSK9 in promoting oxidative-stress-related atherothrombotic process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · cited 1×
“Phase-3 interventional studies demonstrated that both alirocumab and evolocumab reduce cardiovascular events beyond the lipid-lowering effect of the PCSK9 inhibitors (PCSK9i) [18,19], inducing investigations into the so-called pleiotropic effects of inhibiting PCSK9.”
BackgroundGlutathione: overview of its protective roles, measurement, and biosynthesis
Forman, H. J., Zhang, H., & Rinna, A. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.08.006 · Cited by 2,636 · cited 1×
“Other non-enzymatic antioxidants include Vitamins E and C, Coenzyme Q10 and polyphenols that are integrated through the diet [26] and glutathione (GSH), the most abundant low-molecular-weight thiol compound synthesized in cells [27].”
BackgroundEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“Their use reduces circulating LDL-c by about 40–65% when used on top of statins [16,17].”
BackgroundMechanisms of Thrombus Formation
Furie, B., & Furie, B. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801082 · Cited by 1,926 · cited 2×
“TF mediates thrombin generation, leading to, in turn, platelet activation, fibrin generation and, finally, the coagulation cascade activation implicated in thrombus formation [53].”
BackgroundBorén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Role of oxidative stress in atherosclerosis
Harrison, D., Griendling, K. K., Landmesser, U., Hornig, B., & Drexler, H. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03144-2 · Cited by 1,275
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191 · cited 1×
“Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is an enzyme of the serine proteases classes first described in 2003 [9].”
Background
Cited by
Silla, A., Fogacci, F., Punzo, A., Hrelia, S., Simoni, P., Caliceti, C., & Cicero, A. F. G. (2023) · Antioxidants · doi:10.3390/antiox12030578 · Cited by 25
“Moreover, recent experimental evidence underlines the contribution of PCSK9 also in the oxidative state within the arterial wall [16].”
BackgroundTargeting Oxidative Stress in Neurodegenerative Disorders: A Novel Role for PCSK9 Inhibition?
Park, L. M., Pacher, P., & Lohoff, F. W. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00299 · Cited by 16
Su, T., & Si, Y. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.102739 · Cited by 8
Metadata
- Authors
- Cammisotto, V., Baratta, F., Simeone, P. G., Barale, C., Lupia, E., Galardo, G., Santilli, F., Russo, I., & Pignatelli, P.
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2022-03-16
- Volume
- 11
- Issue
- 3
- Pages
- 569
- ISSN
- 2076-3921 (ISSN-L)
- OpenAlex
- W4220911423
- Cited by
- 38
- References
- 16
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.